Cambridge, England (ots/PRNewswire) - Acquisition announced following continuous growth of leading British developer and publisher Global private equity and investment advisory firm CVC Capital Partners (CVC Funds) and Haveli Investments today announced it has agreed to acquire Jagex, a leading developer and publisher of video games. Terms of the transaction were not disclosed. Headquartered in Cambridge, Jagex employs ...
Cambridge, England (ots/PRNewswire) - - OMRON Ventures joins existing investors abrdn, Environmental Technologies Fund and consortium led by Granpool Innovative Investments - Scale-up focused on enabling novel, sustainable scientific innovations that harness the microbiome to solve for 'One Health' challenges, ...
Cambridge, England (ots/PRNewswire) - - Funds to support scale-up, including continued development of AI-augmented knowledge discovery platform, the e[datascientist]™, and continued international expansion - Platform business focused on bridging the current 'translation gap', addressing critical bottlenecks in the ...
Cambridge, England (ots/PRNewswire) - Abcam plc ("Abcam", "Company", "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following trading update for the six-month period ending 30 June 2022. The Company will release its full results for the six-month period on 12 September 2022. The Group expects to report total revenues for the six-month period of ...
Cambridge, England (ots/PRNewswire) - Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today announces the appointment of Tommy Thomas as Vice President of Investor Relations. Tommy, who will be based in our Waltham, MA office, has over 20 years' experience in the life sciences sector, largely focused in the area of research tools. He joins ...
Cambridge, England (ots/PRNewswire) - CAMBRIDGE, England, March 25, 2022 Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance ...
Cambridge, England (ots/PRNewswire) - CAMBRIDGE, England, March 25, 2022 Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance ...
Fremont, Calif. and Cambridge, England (ots/PRNewswire) - Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of ...
Abcam; Nautilus Biotechnology, Inc.
Seattle and Cambridge, England (ots/PRNewswire) - Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a ...
Cambridge, England (ots/PRNewswire) - - Completing $340m strategic acquisition of BioVision - Expanding facilities in Eugene, further growing kits and assays portfolio - Supporting the growing demand of the sector and accelerating execution of strategic plan Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announces the ...
South San Francisco, Calif. and Cambridge, England (ots/PRNewswire) - - The partnership will support the progression of PY314, the first of Pionyr's Myeloid Tuning(TM) antibodies to enter the clinic - Pionyr will use Abcam's EPR20243 clone to evaluate TREM2 levels in tissue samples for potential future development ...
Cambridge, England (ots/PRNewswire) - Novogene Europe, a leading provider of genomic services and solutions, has announced the launch of a Clinical Service to provide its European customers with next-generation sequencing (NGS) services and solutions for their clinical samples. The Clinical Service has launched after Novogene's Cambridge Sequencing Centre was awarded ...
Cambridge, England (ots/PRNewswire) - - State-of-the-art site will enable rapid delivery of engineered cell lines - Powering ready-to-use edited cell-line portfolio expansion - Enable comprehensive customization for research, diagnostic and therapeutic development Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the opening of a new 16,000 sq ft purpose-fitted facility ...
London and Cambridge, England (ots/PRNewswire) - - Long-term partnership to facilitate cancer research through development of custom antibodies - Agreement to enable global access to resulting reagents and potential diagnostics Today, Cancer Research UK, the world's largest independent funder of cancer research and Abcam plc, a global innovator in life science reagents ...
Cambridge Quantum Computing Limited
Cambridge, England (ots/PRNewswire) - Cambridge Quantum Computing ("CQC") announces that they have used the "natively quantum" structure of natural language to open up an entirely new realm of possible applications by translating grammatical sentences into quantum circuits, and then implementing the resulting ...
Cambridge, England and Milpitas, California (ots/PRNewswire) - Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life science research and diagnostic ...
Cambridge, England (ots/PRNewswire) - - Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSure(TM) - Opportunity to combine Expedeon and Abcam's technologies to create new products to support research and diagnostic development Abcam plc, a global innovator in life ...
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY - Study will enrol 200 adult patients with limb trauma who are rescued by helicopter - Efficacy, tolerability and practicality of use of the inhaled analgesic in hostile mountain environments to be investigated Cambridge, England (ots/PRNewswire) - The Mundipharma network ...
Cambridge, England (ots/PRNewswire) - - flutiform k-haler is now available in Europe as an asthma treatment for adults and adolescents (aged 12 years and older)[1] - Research indicates that many patients make errors with their inhalers and this is associated with poor asthma control and increased exacerbations[2] - ...
Cambridge, England (ots/PRNewswire) - SciBite (http://www.scibite.com/), a firm whose technology is disrupting the traditional approaches of working with scientific information across the globe, today announced a strategic partnership with ONTOFORCE, the leading data integration company. (Logo: http://mma.prnewswire.com/media/617446/SciBite_Logo.jpg ) (Logo: ...
Cambridge, England (ots/PRNewswire) - SciBite (https://www.scibite.com/), the award-winning semantic analytics company, today announced a strategic partnership with ChemAxon (https://chemaxon.com/), the leading cheminformatics company, enabling Pharmaceutical companies to capitalise on unlocking the wealth of R&D data that is at their disposal. (Logo: ...
Cambridge, England (ots/PRNewswire) - - First presentation of largest ever real-world flutiform® study at European Respiratory Society International Congress involving over 2,500 patients - Proportion of patients with well-controlled asthma more than doubled 12 months after switching to flutiform pMDI New ...
Cambridge, England (ots/PRNewswire) - - flutiform k-haler achieved high levels of lung deposition of over 44% of delivered dose - Plume force of flutiform k-haler was compared with fluticasone propionate/salmeterol xinafoate delivered via the Seretide® Evohaler® pMDI and Sirdupla® pMDI devices - Pharmacokinetic ...
Tokyo and Cambridge, England (ots/PRNewswire) - SciBite - The award-winning semantic analytics company, today announced that GlaxoSmithKline K.K. (hereinafter referred to as GSK Japan), one of Japan's leading research-based pharmaceutical and healthcare companies, has selected SciBite's Semantic Platform to enhance ...
Cambridge, England (ots/PRNewswire) - Mundipharma announced today that they have submitted a file to the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA) seeking a licence for its new product flutiform® K-Haler®. The indication sought is for the treatment of asthma in adults and adolescents where the use of a combination product ...
Cambridge, England (ots/PRNewswire) - Real-time Cyber Threat Detection for SCADA Now Available Darktrace, the leader in Enterprise Immune System technology, has announced the launch of the Industrial Immune System, a new product capable of detecting emerging cyber-threats within Industrial Control Systems (ICS). Applying Darktrace's machine learning and mathematics to ...
Cambridge, England (ots/PRNewswire) - Mundipharma Research Limited (Mundipharma) announced today a major milestone in the development programme of flutiform(R)(fluticasone propionate / formoterol fumarate) for the treatment of Chronic Obstructive Pulmonary Disease (COPD) with the commencement of a key clinical trial. COPD is a life-threatening lung disease that interferes with normal breathing, estimated to affect at least 64 million people worldwide[1]. The first patient in ...
Amsterdam, Cambridge, England And Clinton, New Jersey (ots/PRNewswire) - Echo Pharmaceuticals ("Echo") announces that Namisol(R) has completed successfully a Phase II trial with 24 patients suffering from spasticity and pain due to multiple sclerosis (MS). The trial has been conducted by the Centre for Human Drug ...
Cambridge, England (ots/PRNewswire) - NOT INTENDED FOR MEDIA IN THE NETHERLANDS -Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; ...
Cambridge, England (ots/PRNewswire) - - Total of 43 bendamustine abstracts to be presented at ASH, including five oral presentations - New data supports use of bendamustine-rituximab (B-R) regimen in indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) 43 abstracts, announcing the results of studies ...